Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst

  • Last week, Inventiva IVA announced a licensing and collaboration agreement with Sino Biopharm's subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ) to develop and commercialize lanifibranor in Greater China
  • Regardless of CTTQ's decision on lanifibranor's clinical development pathway in China, HC Wainwright notes that Sino Biopharm is a vertically-integrated company with substantial R&D, manufacturing, sales, and marketing capability.
  • The analyst regards the collaboration as a financially prudent pathway for lanifibranor's expansion to a major NASH market, given Sino Biopharm's experience as a commercial-stage company in Greater China.
  • HC Wainwright affirms a Buy rating but lowered the price target from $42 to $36 based on the expected enrollment delay for the pivotal Phase 3 NATiV3 trial.
  • The analyst adjusted the projected sales trajectory of lanifibranor for the treatment of NASH to reflect the latest clinical timeline (last patient's first visit in 2H23, and top-line data readout in 2H25).
  • These changes reduced the analyst's projected peak revenues of lanifibranor in NASH to €1.7 billion in 2034 (previously €1.9 billion).
  • Price Action: IVA shares are up 0.26% at $3.93 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CarePrice TargetReiterationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!